Jasper Therapeutics Inc (JSPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.71+3.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JSPR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress KP-104 through Phase 2 basket trial stages in rare renal indications and plan Phase 3 initiation for PNH with FDA engagement.
Stated as a priority in 2 quarters including 2026-Q2. Management emphasizes KP-104's advancement with interim Phase 2 basket trial data expected in Q4 2026 and plans for an end-of-Phase 2 FDA meeting in H1 2027 to support Phase 3 initiation for PNH. Financials show continued operating losses consistent with clinical development stage. The trajectory is delivering on stated clinical development milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“KP-104 Phase 2 basket trial interim data expected Q4 2026; end-of-Phase 2 FDA meeting planned for PNH in H1 2027.”
“KP-104 is Phase 2/3 ready with potential best-in-disease profile targeting complement cascade.”
Progress briquilimab towards a pre-BLA meeting for SCID and update clinical development plans for mast-cell mediated diseases.
Stated as a priority in 2 quarters including 2026-Q1 and 2026-Q2. Management reports progress towards a pre-BLA meeting with FDA for briquilimab in SCID and plans to announce next steps in early 2027. Clinical development protocol updates and data analyses have been conducted. Financials reflect ongoing R&D expenses consistent with advancing clinical programs. The trajectory shows continued advancement aligned with stated plans.
“Progressing towards pre-BLA meeting with FDA for briquilimab in SCID; next steps expected in Q1 2027.”
“Advancing briquilimab development program in CSU; Phase 2b protocol updated and refiled with FDA.”
Finalize acquisition of Kira and integrate operations to advance a consolidated portfolio of immunology therapies.
Newly stated in 2026-Q2. Management completed the acquisition of Kira Pharmaceuticals in July 2026 and emphasizes the combined company's focus on advancing a consolidated pipeline. Financials show a cash balance of $7.3 million as of June 30, 2026, post-acquisition. The trajectory reflects initial integration with plans to leverage combined assets.
“Acquisition of Kira Pharmaceuticals closed in July creating combined company with robust portfolio.”
Secure financing to support clinical development and operating expenses through the second half of 2028.
Newly stated in 2026-Q2. Management completed a $132 million private placement concurrent with the Kira acquisition to fund operations through the second half of 2028. Cash and cash equivalents were $7.3 million as of June 30, 2026, reflecting use of proceeds. The financing supports planned clinical milestones and operating expenses, indicating delivery on capital raising objectives.
“Completed $132 million private placement financing concurrent with Kira acquisition.”
File CTA/IND for KP-701 in early 2027 and report first-in-human data in Q3 2027.
Newly stated in 2026-Q2. Management plans to file a clinical trial application or investigational new drug application for KP-701 in Q1 2027 and expects first-in-human data by Q3 2027. Financials show ongoing operating losses consistent with early-stage clinical development. The trajectory is aligned with planned clinical initiation milestones.
“KP-701 expected to file CTA/IND in Q1 2027 and report first-in-human data in Q3 2027.”
Over the trailing year it converted 1.32x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
16 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.